Red Light Therapy Boosts Memory and Brain Activity in Aging Rats
Transcranial photobiomodulation improved spatial memory and cognitive flexibility in middle-aged rats by modulating key memory-circuit biomarkers.
Summary
Researchers applied near-infrared light (810 nm) to the prefrontal cortex of 9-month-old rats for 11 days and found meaningful improvements in spatial memory and cognitive flexibility. Brain analyses revealed reduced cytochrome c oxidase activity across limbic-cortical regions — including the prefrontal cortex, hippocampus, and septum — alongside increased c-Fos expression in the dorsal dentate gyrus, a region critical for memory encoding. Anxiety levels and locomotor activity were unchanged, suggesting the effects were cognitively specific. The findings support photobiomodulation as a promising, non-invasive approach to counteract age-related cognitive decline by optimizing mitochondrial function and neural circuit engagement in memory-relevant brain areas.
Detailed Summary
Cognitive decline is one of the most consequential hallmarks of aging, and finding safe, non-pharmacological interventions to slow or reverse it remains a major research priority. Photobiomodulation (PBM) — the therapeutic use of low-level near-infrared or red light — has attracted growing attention for its ability to enhance mitochondrial energy production and support neuroplasticity, but its effects on aging brains require deeper characterization.
In this study, researchers at the University of Oviedo administered automatic transcranial PBM at 810 nm over the prefrontal cortex of 9-month-old Wistar rats — equivalent to early middle age — for 11 consecutive days at 12 minutes per session. Animals were then assessed for spatial memory, cognitive flexibility, anxiety-like behavior, and locomotor activity using validated behavioral tasks.
PBM-treated rats showed significant improvements in spatial memory and cognitive flexibility compared to controls. Critically, no changes were seen in anxiety or motor function, indicating the cognitive benefits were not confounded by altered activity levels or stress responses.
At the neurobiological level, PBM reduced cytochrome c oxidase (CCO) activity in several limbic-cortical regions including the prefrontal cortex, CA1 and CA3 hippocampal subfields, septum, and lateral mammillary nuclei. This reduction may reflect a recalibration of mitochondrial metabolism toward greater efficiency. Simultaneously, c-Fos expression — a marker of neuronal activation — increased in the dorsal dentate gyrus, pointing to enhanced memory encoding and retrieval capacity in this region.
While the results are encouraging, this study used only male middle-aged rats, limiting generalizability. Optimal stimulation parameters, long-term durability of effects, and sex-specific responses remain to be established. Translation to human clinical settings will require rigorous dose-finding studies and validated automated delivery systems.
Key Findings
- 11 days of transcranial 810 nm PBM improved spatial memory and cognitive flexibility in middle-aged rats.
- Anxiety-like behavior and locomotor activity were unchanged, isolating cognitive-specific effects.
- CCO activity decreased in prefrontal cortex, hippocampal CA1/CA3, septum, and mammillary nuclei after PBM.
- c-Fos expression increased in the dorsal dentate gyrus, indicating enhanced neuronal activation in memory circuits.
- Results support PBM as a non-invasive mitochondrial and neural plasticity modulator for aging brains.
Methodology
9-month-old male Wistar rats received automated transcranial PBM (810 nm, 12 min/day) over the prefrontal cortex for 11 consecutive days. Behavioral outcomes included spatial memory and cognitive flexibility tasks; neurobiological endpoints were CCO histochemistry and c-Fos immunohistochemistry across limbic-cortical regions.
Study Limitations
The study used only male middle-aged rats, limiting generalizability across sexes and older age groups. Optimal parameters such as wavelength, dose, and session duration are not yet standardized, and the durability of cognitive benefits beyond the treatment window was not assessed. Human translation requires further dose-response and long-term safety studies.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: